SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 454.95 |
Enterprise Value ($M) | 404.70 |
Book Value ($M) | -8.80 |
Book Value / Share | -0.19 |
Price / Book | -51.68 |
NCAV ($M) | -18.38 |
NCAV / Share | -0.40 |
Price / NCAV | -24.75 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.09 |
Return on Assets (ROA) | -0.63 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 5.81 |
Current Ratio | 6.01 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 276.13 |
Assets | 285.71 |
Liabilities | 294.51 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 90.40 |
Operating Income | -96.78 |
Net Income | -126.87 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -96.77 |
Cash from Investing | -20.61 |
Cash from Financing | 194.62 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Menora Mivtachim Holdings Ltd. | 4.99 | 0.00 | |
13G/A | Adage Capital Management, L.P. | 6.94 | -21.62 | |
13G/A | Morgan Stanley | 1.80 | -65.34 | |
13D/A | Pontifax Management III G.P. (2011) Ltd. | 4.40 | -30.85 | |
13G/A | Ra Capital Management, L.p. | 7.10 | 3.98 | |
13G/A | Rtw Investments, Lp | 9.99 | 185.51 | |
13G/A | Point72 Asset Management, L.P. | 3.60 | -40.85 | |
13G/A | Great Point Partners Llc | 1.80 | -71.04 | |
13G/A | Cowen And Company, Llc | 4.30 | -21.77 | |
13G | BlackRock, Inc. | 5.90 | 0.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
294,817 | 2,140,909 | 13.77 | |
31,939 | 232,049 | 13.76 | |
37,828 | 530,402 | 7.13 | |
49,752 | 1,139,359 | 4.37 | |
(click for more detail) |
Similar Companies | |
---|---|
TRDA – Entrada Therapeutics, Inc. | TRVI – Trevi Therapeutics, Inc. |
TVTX – Travere Therapeutics, Inc. | VCEL – Vericel Corporation |
VERA – Vera Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io